2021
October 5, 2021
IM Therapeutics to Present at the B & T Cell-Mediated Autoimmune Disease Drug Development Summit, October 5-7, 2021 | READ MORE
August 2, 2021
In the News: BioBoss Podcast, CEO Nandan Padukone discusses leadership and how IM Therapeutics is targeting the root cause of autoimmunity with therapeutics directed at human leukocyte antigens which are a window to the broader autoimmune spectrum | READ MORE
July 21, 2021
In the News: FierceBiotech, IM Therapeutics posts positive, early results for oral Type 1 diabetes hopeful | READ MORE
July 21, 2021
IM Therapeutics Reports Positive Results in Safety, Tolerability and Mechanism of Action of Phase 1b Trial of Lead Drug IMT-002 in Type 1 Diabetes | READ MORE
July 20, 2021
IM Therapeutics to Present at LifeSci Partners Summer Symposium on July 21, 2021 | READ MORE
June 24, 2021
IM Therapeutics Co-Founder and CMO Peter Gottlieb, M.D., to Present Advances in Genetically Targeted Therapies for Type 1 Diabetes at the 2021 ADA Scientific Sessions | READ MORE
June 1, 2021
Life Science Leader: Companies To Watch: IM Therapeutics | READ MORE
April 23, 2021
European Pharmaceutical Review: A new small molecule drug discovery and development platform for HLA-associated autoimmune diseases | READ MORE
April 6, 2021
IM Therapeutics Expands Management Team with David Alleva, Ph.D. as VP, Immunology | READ MORE
March 18, 2021
Chemistry World: The Life of a Chief Scientific Officer | READ MORE
January 27, 2021
IM Therapeutics Announces Appointment of Jonathan Rigby to Board of Directors | READ MORE
2020
October 29, 2020
IM Therapeutics Launches Phase 1b Trial of Lead Drug IMT-002 in Autoimmunity; Announces Positive Safety Data of Phase 1a Study | READ MORE
October 7, 2020
Pre-Screening Makes a Significant Impact on Type 1 Diabetes (JDRF) | READ MORE
August 3, 2020
IM Therapeutics to Present at LifeSci Partners Summer Symposium on August 4, 2020 | READ MORE
July 9, 2020: In the News
IM Therapeutics Brings First Personalized, Oral Therapy for Insulin Regulation to Clinical Trials | READ MORE
July 8, 2020
IM Therapeutics Expands Management Team with Appointments of Tom Shea as CFO/COO and Dr. Sarah Bird as VP, Clinical Development | READ MORE
June 24, 2020
IM Therapeutics Announces First Patient Dosed in Phase 1 Study of its Lead Drug IMT-002 for Type 1 Diabetes | READ MORE
February 25, 2020
IM Therapeutics to Present Advances of its Technology Platform in Developing Therapies for Autoimmune Disease | READ MORE
February 19, 2020
IM Therapeutics Presents Clinical Advances at Advanced Technologies and Treatments for Diabetes (AATD) | READ MORE
February 7, 2020
IM Therapeutics Announces Appointment of Dr. Stephen Dilly to Board of Directors | READ MORE
February 3, 2020
JDRF T1D Fund and JDRF Release Report on the Total Economic Value of Novel Type 1 Diabetes Therapeutic Concepts | T1DFund.org
2019
October 9, 2019
IM Therapeutics Raises $10 Million Financing Co-Led by JDRF T1D Fund and Morningside Ventures | READ MORE
2018
November 14, 2018
ImmunoMolecular Therapeutics Awarded SBIR Grant and Receives Rare Pediatric Disease Designation from FDA for IMT-002 | READ MORE
June 25, 2018
ImmunoMolecular Therapeutics’ Scientific Co-founder Presents a Novel Small Molecule Approach to Blocking the Autoimmunity in Type 1 Diabetes | READ MORE
February 15, 2018
ImmunoMolecular Therapeutics Announces Publication of a Novel Small Molecule Approach to Blocking the Autoimmunity in Type 1 Diabetes | READ MORE
2017
December 21, 2017
ImmunoMolecular Therapeutics To Present at the 10th Annual Biotech Showcase | READ MORE
December 6, 2017
ImmunoMolecular Therapeutics Announces Two Issued Patents For Small Molecule Therapies in Type 1 Diabetes and Celiac Disease | READ MORE
November 9, 2017
ImmunoMolecular Therapeutics Launches to Advance Innovative Immunotherapies for Genetically Defined Type 1 Diabetes and Other Autoimmune Diseases | READ MORE